Phase Ib/IIa trial of single and multiple doses of MG 1703 in patients with advanced solid tumours.
Phase of Trial: Phase I
Latest Information Update: 02 Dec 2014
At a glance
- Drugs Lefitolimod (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Mologen
- 30 Sep 2010 A further evaluation sequence of data was reported in a Mologen media release.
- 30 Sep 2010 Status changed from active, no longer recruiting to completed, according to a Mologen media release.
- 09 Jun 2010 Results, including an evaluation of efficacy, have been reported in a Mologen media release. Results have also been reported at the conference of the American Society of Gene and Cell Therapy.